Intestinal Cell News

Intestinal Cell News is an online resource that curates the latest research using intestinal cells.

Growth of the Maternal Intestine during Reproduction

March 20, 2025

[Cell] Using the mouse intestine, a striking and tractable model of organ resizing, researchers found that reproductive remodeling was anticipatory and distinct from diet- or microbiota-induced resizing.

PTK6 Drives HNRNPH1 Phase Separation to Activate Autophagy and Suppress Apoptosis in Colorectal Cancer

March 19, 2025

[Autophagy] Researchers discovered that protein tyrosine kinase 6 (PTK6) could activate autophagy and inhibit colorectal cancer apoptosis.

Comprehensive Metabolomic and Epigenomic Characterization of Microsatellite Stable BRAF-Mutated Colorectal Cancer

March 18, 2025

[Oncogene] The authors characterized the metabolomic, epigenetic, and transcriptomic patterns of altogether 39 microsatellite stable BRAF-mutated colorectal cancers.

THSD7A As a Novel Prognostic Factor for Colorectal Carcinoma

March 18, 2025

[BMC Gastroenterology] Scientists investigated the prognostic value of thrombospondin type 1 domain-containing 7 A (THSD7A) expression in colorectal cancer.

KIF3C Inhibits the Progression and Proliferation of Colorectal Cancer

March 17, 2025

[BMC Gastroenterology] Reearchers demonstrated that KIF3C was highly expressed in cells and tissues of colorecal cancer, and this expression was closely associated with tumor prognosis.

PD-1 Antibody Camrelizumab Plus Apatinib and SOX As First-Line Treatment in Patients with AFP-Producing Gastric or Gastro-Esophageal Junction Adenocarcinoma (CAP 06): A Multi-Center, Single-Arm,...

March 17, 2025

[Signal Transduction and Targeted Therapy] This Phase II trial evaluated the antitumor activity, safety, and biomarkers of camrelizumab plus apatinib and S-1 and oxaliplatin followed by treatment with camrelizumab plus apatinib, as a first-line treatment in patients with alpha-fetoprotein-producing gastric or gastro-esophageal junction adenocarcinoma.

Piezo1 Promotes the Progression of Necrotizing Enterocolitis by Activating the Ca2(+)/CaMKII-Dependent Pathway

March 17, 2025

[Communications Biology] Scientists demonstrated that the cation-channel Piezo1 was expressed in both neonatal and murine intestinal epithelial cells (IECs). Mice lacking Piezo1 in IECs exhibited resistance to necrotizing enterocolitis owing to the impaired inflammatory mediators.

CBX2 As a Therapeutic Target in Colorectal Cancer: Insights into the Altered Chromatin Accessibility via RUNX1-CBX2-MAP4K1 Axis

March 14, 2025

[Oncogene] Gain and loss of function studies demonstrated that chromobox homolog 2 (CBX2) significantly promoted colorectal cancer (CRC) progression and chemoresistance in cell lines, patient-derived CRC organoids and xenografts.

Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients: The SAKK 41/13 – Prospective Randomized Placebo-Controlled Double-Blind Trial

March 14, 2025

[Clinical Cancer Research] Investigators assessed the benefit of adjuvant aspirin in resected PIK3CA-mutated colon cancer patients. Patients with resected colon cancer stage II and III harbouring an activating PIK3CA mutation were included.

Phase II Study of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, and S-1 with Surgery, and Adjuvant Durvalumab Plus S-1 for Resectable Locally Advanced Gastric Cancer

March 14, 2025

[Journal For Immunotherapy of Cancer] This Phase II study evaluated the efficacy and safety of combining neoadjuvant durvalumab with docetaxel, oxaliplatin, and S-1, followed by surgery and adjuvant durvalumab plus S-1 chemotherapy, for resectable locally advanced gastric cancer.

KLF6-Mediated Recruitment of the P300 Complex Enhances H3K23su and Cooperatively Upregulates SEMA3C with FOSL2 to Drive 5-FU Resistance in Colon Cancer Cells

March 14, 2025

[Experimental & Molecular Medicine] Researchers demonstrated that histone 3 lysine 23 succinylation (H3K23su) was a critical epigenetic determinant of 5-fluorouracil (5-FU) resistance in colon cancer cells, exerting its effects through the modulation of critical genes and transcription factors.

USP10/XAB2/ANXA2 Axis Promotes DNA Damage Repair to Enhance Chemoresistance to Oxaliplatin in Colorectal Cancer

March 14, 2025

[Journal of Experimental & Clinical Cancer Research] Colorectal cancer cells treated with oxaliplatin exhibited increased ubiquitin-specific protease 10 (USP10) nuclear expression. USP10 bound to XPA binding protein 2 (XAB2) and deubiquitinated XAB2 K48-linked polyubiquitination at K593, thereby stabilising XAB2 by reducing its degradation.

Since 2015, Intestinal Cell News has been a valuable resource for keeping researchers and medical professionals updated on the latest publications, news and events in the field of gastrointestinal cell biology. Our editorial team collects and publishes the most current articles and reviews using stomach, colon, and small and large intestinal cells. We cover topics including the culturing of intestinal cells, intestinal organoids, intestinal cancers, and gastrointestinal conditions such as irritable bowel syndrome and Crohn’s disease.